Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field

LIU Gege; CHEN Wang

doi:10.6039/j.issn.1001-0408.2023.08.23

您当前的位置：

首页 >

文章列表页 >

Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field

更新时间：2023-04-25

- Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field
- ZHONGGUO YAOFANG Vol. 34, Issue 8, Pages: 1014-1019(2023)
- 作者机构：
  
  1.陕西理工大学生物科学与工程学院，陕西汉中;723001
  2.陕西理工大学秦巴生物资源与生态环境省部共建国家重点实验室（培育），陕西汉中　723001
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.08.23
  CLC： R96
- Published：30 April 2023，
  
  Received：13 September 2022，
  
  Revised：12 February 2023，
扫描看全文
刘格歌,陈旺.Hedgehog信号通路抑制剂在抗肿瘤领域的研究进展 ^Δ[J].中国药房,2023,34(08):1014-1019.

LIU Gege,CHEN Wang.Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field[J].ZHONGGUO YAOFANG,2023,34(08):1014-1019.
刘格歌,陈旺.Hedgehog信号通路抑制剂在抗肿瘤领域的研究进展 ^Δ[J].中国药房,2023,34(08):1014-1019. DOI： 10.6039/j.issn.1001-0408.2023.08.23.

LIU Gege,CHEN Wang.Research progress of Hedgehog signaling pathway inhibitors in anti-tumor field[J].ZHONGGUO YAOFANG,2023,34(08):1014-1019. DOI： 10.6039/j.issn.1001-0408.2023.08.23.

摘要

Hedgehog（Hh）信号通路在细胞增殖分化、组织形成等过程中发挥着重要的调节作用，适当的Hh信号强度及作用时间对机体各组织的正常发育至关重要，而其异常活化会导致乳腺癌、肝癌、胰腺癌、肺癌等多种恶性肿瘤的发生与发展，这使得Hh途径成为抗肿瘤药物研发的理想靶点。目前，Hh信号通路抑制剂主要作用靶点包括Hh配体、受体Smoothened（Smo）及转录因子Gli。其中，依赖于Hh配体途径的化合物因无法作用于非经典Hh信号通路仍停留在实验室研究层面；Smo蛋白的特殊结构使之能与药物高效、选择性地结合，是一个强大而有效的药物作用靶点，因而Smo选择性抑制剂一直是相关研究的活跃领域，且已有多个Smo抑制剂进入临床使用或试验阶段；Gli能调控多个致癌基因，促进细胞异常增殖而导致肿瘤的发生，还可对Hh信号通路进行反馈抑制，因此研发能够抑制Gli活性的药物具有广阔前景。在今后的研发中，可考虑设计作用于多种通路抑制剂，以避免耐药性和其他副作用的出现。

Abstract

Hedgehog （Hh） signaling pathway plays an important regulatory role in the process of cell proliferation， differentiation and tissue formation. Proper intensity and action time of Hh signal are crucial for the normal development of various tissues of the body， and its abnormal activation will lead to the occurrence and development of most malignant tumors， including breast cancer， liver cancer， pancreatic cancer， and lung cancer， which makes Hh signaling pathway an ideal target for anti-tumor drug research and development. At present， the main targets of Hh signaling pathway inhibitors include Hh ligand， receptor Smoothened （Smo） and transcription factor Gli. Among them， the compounds that depend on the Hh ligand pathway still remain at the stage of laboratory research because they cannot act on the non-classical Hh signaling pathway. The special structure of Smo protein enables it to combine with drugs efficiently and selectively， which is a powerful and effective drug target. Therefore， Smo selective inhibitors have been an active field of related research， and many Smo inhibitors have entered the clinical use or trial stage. Gli can regulate multiple carcinogenic genes， promote abnormal cell proliferation and lead to tumor， and can also cause feedback inhibition to Hh signaling pathway. Therefore， the development of drugs that can inhibit the activity of Gli has broad prospects. In the future， a combination of multiple pathway inhibitors can be designed to avoid drug resistance and other side effects.

关键词

Hedgehog信号通路抑制剂抗肿瘤进展

Keywords

inhibitorsanti-tumorprogress

references

NÜSSLEIN-VOLHARD C，WIESCHAUS E. Mutations affecting segment number and polarity in Drosophila[J]. Nature，1980，287（5785）：795-801.

BRISCOE J，THÉROND P P. The mechanisms of hedgehog signalling and its roles in development and disease[J]. Nat Rev Mol Cell Biol，2013，14（7）：416-429.

ROBBINS D J，FEI D L，RIOBO N A. The hedgehog signal transduction network[J]. Sci Signal，2012，5（246）：re6.

MARIGO V，DAVEY R A，ZUO Y，et al. Biochemical evidence that patched is the hedgehog receptor[J]. Nature，1996，384（6605）：176-179.

ZHULYN O，NIEUWENHUIS E，LIU Y C，et al. Ptch2 shares overlapping functions with Ptch1 in Smo regulation and limb development[J]. Dev Biol，2015，397（2）：191-202.

WANG B L，FALLON J L，BEACHY P A. Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb[J]. Cell，2000，100（4）：423-434.

WU F J，ZHANG Y，SUN B，et al. Hedgehog signaling：from basic biology to cancer therapy[J]. Cell Chem Biol，2017，24（3）：252-280.

HUANGFU D W，LIU A M，RAKEMAN A S，et al. Hedgehog signalling in the mouse requires intraflagellar transport proteins[J]. Nature，2003，426（6962）：83-87.

PIETROBONO S，GAGLIARDI S，STECCA B. Non-canonical hedgehog signaling pathway in cancer：activation of GLI transcription factors beyond smoothened[J]. Front Genet，2019，10：556.

NIYAZ M，KHAN M S，MUDASSAR S. Hedgehog signaling：an Achilles’ heel in cancer[J]. Transl Oncol，2019，12（10）：1334-1344.

SARI I N，PHI L T H，JUN N，et al. Hedgehog signaling in cancer：a prospective therapeutic target for eradicating cancer stem cells[J]. Cells，2018，7（11）：208.

BIAN Y H，HUANG S H，YANG L，et al. Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas[J]. World J Gastroenterol，2007，13（11）：1659-1665.

DING J，LI H Y，ZHANG L，et al. Hedgehog signaling，a critical pathway governing the development and progression of hepatocellular carcinoma[J]. Cells，2021，10（1）：123.

BAILEY J M，MOHR A M，HOLLINGSWORTH M A. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer[J]. Oncogene，2009，28（40）：3513-3525.

MEHLMAN C，TAKAM KAMGA P，COSTANTINI A，et al. Baseline hedgehog pathway activation and increase of plasma Wnt1 protein are associated with resistance to immune checkpoint inhibitors in advanced non-small-cell lung cancer[J]. Cancers （Basel），2021，13（5）：1107.

SAQUI-SALCES M，MERCHANT J L. Hedgehog sig- naling and gastrointestinal cancer[J]. Biochim Biophys Acta，2010，1803（7）：786-795.

MANZELLA G，SCHÄFER B W. Interfering with hedgehog pathway：new avenues for targeted therapy in rhabdomyosarcoma[J]. Curr Drug Targets，2016，17（11）：1228-1234.

MARTINELLI G，OEHLER V G，PAPAYANNIDIS C，et al. Treatment with PF-04449913，an oral smoothened antagonist，in patients with myeloid malignancies：a phase 1 safety and pharmacokinetics study[J]. Lancet Haematol，2015，2（8）：e339-e346.

CHANG Q，FOLTZ W D，CHAUDARY N，et al. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition[J]. Int J Cancer，2013，133（1）：225-234.

PETROVA E，RIOS-ESTEVES J，OUERFELLI O，et al. Inhibitors of Hedgehog acyltransferase block sonic hedgehog signaling[J]. Nat Chem Biol，2013，9（4）：247-249.

OWENS A E，DE PAOLA I，HANSEN W A，et al. Design and evolution of a macrocyclic peptide inhibitor of the sonic hedgehog/Patched interaction[J]. J Am Chem Soc，2017，139（36）：12559-12568.

NACHTERGAELE S，MYDOCK L K，KRISHNAN K，et al. Oxysterols are allosteric activators of the oncoprotein smoothened[J]. Nat Chem Biol，2012，8（2）：211-220.

WANG Y，DAVIDOW L，ARVANITES A C，et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity[J]. Chem Biol，2012，19（8）：972-982.

NEDELCU D，LIU J，XU Y Q，et al. Oxysterol binding to the extracellular domain of Smoothened in hedgehog signaling[J]. Nat Chem Biol，2013，9（9）：557-564.

WANG J，ZHANG Y，HUANG W J，et al. ABT-199 inhi-bits hedgehog pathway by acting as a competitive inhibitor of oxysterol，rather as a BH3 mimetic[J]. Acta Pharmacol Sin，2021，42（6）：1005-1013.

TAO H Y，JIN Q H，KOO D I，et al. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened[J]. Chem Biol，2011，18（4）：432-437.

ROBARGE K D，BRUNTON S A，CASTANEDO G M，et al. GDC-0449-a potent inhibitor of the hedgehog pathway[J]. Bioorg Med Chem Lett，2009，19（19）：5576-5581.

PAN S F，WU X，JIANG J Q，et al. Discovery of NVP-LDE225，a potent and selective smoothened antagonist[J]. ACS Med Chem Lett，2010，1（3）：130-134.

MUNCHHOF M J，LI Q F，SHAVNYA A，et al. Disco-very of PF-04449913，a potent and orally bioavailable inhibitor of smoothened[J]. ACS Med Chem Lett，2012，3（2）：106-111.

YAUCH R L，DIJKGRAAF G J，ALICKE B，et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma[J]. Science，2009，326（5952）：572-574.

TREMBLAY M R，LESCARBEAU A，GROGAN M J，et al. Discovery of a potent and orally active hedgehog pathway antagonist （IPI-926）[J]. J Med Chem，2009，52（14）：4400-4418.

SIU L L，PAPADOPOULOS K，ALBERTS S R，et al. A first-in-human，phase Ⅰ study of an oral hedgehog （Hh）pathway antagonist，BMS-833923 （XL139），in subjects with advanced or metastatic solid tumors[J]. J Clin Oncol，2010，28（15_suppl）：2501.

KIM J，TANG J Y，GONG R Y，et al. Itraconazole，a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth[J]. Cancer Cell，2010，17（4）：388-399.

KIM D J，KIM J，SPAUNHURST K，et al. Open-label，exploratory phase Ⅱ trial of oral itraconazole for the treatment of basal cell carcinoma[J]. J Clin Oncol，2014，32（8）：745-751.

KELLY R J，ANSARI A M，MIYASHITA T，et al. Targe-ting the hedgehog pathway using itraconazole to prevent progression of barrett’s esophagus to invasive esophageal adenocarcinoma[J]. Ann Surg，2021，273（6）：e206-e213.

MILLER-MOSLIN K，PEUKERT S，JAIN R K，et al. 1-amino-4-benzylphthalazines as orally bioavailable smoo-thened antagonists with antitumor activity[J]. J Med Chem，2009，52（13）：3954-3968.

PEUKERT S，HE F，DAI M，et al. Discovery of NVP-LEQ506，a second-generation inhibitor of smoothened[J]. ChemMedChem，2013，8（8）：1261-1265.

JIN G H，SIVARAMAN A，LEE K. Development of taladegib as a sonic hedgehog signaling pathway inhibitor[J]. Arch Pharm Res，2017，40（12）：1390-1393.

OAK A S W，BOCHEVA G，KIM T K，et al. Noncalcemic vitamin D hydroxyderivatives inhibit human oral squamous cell carcinoma and down-regulate hedgehog and WNT/β-catenin pathways[J]. Anticancer Res，2020，40（5）：2467-2474.

TANG J Y，XIAO T Z，ODA Y，et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas[J]. Cancer Prev Res （Phila），2011，4（5）：744-751.

DEBERARDINIS A M，RACCUIA D S，THOMPSON E N，et al. Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors[J]. Eur J Med Chem，2015，93：156-171.

BANERJEE U，DEBERARDINIS A M，HADDEN M K. Design，synthesis，and evaluation of hybrid vitamin D3 side chain analogues as hedgehog pathway inhibitors[J]. Bioorg Med Chem，2015，23（3）：548-555.

MASCHINOT C A，HADDEN M K. Synthesis and eva-luation of vitamin D3 analogues with C-11 modifications as inhibitors of hedgehog signaling[J]. Bioorg Med Chem Lett，2017，27（17）：4011-4014.

赵伟利，董肖椿，陆秀宏，等. 吡唑酞嗪化合物及其制备方法和用途：CN105985321B[P]. 2018-10-26.

HOCH L，FAURE H，ROUDAUT H，et al. MRT-92 inhi-bits hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the smoothened receptor[J]. FASEB J，2015，29（5）：1817-1829.

LIN P，HE Y M，CHEN G D，et al. A novel hedgehog inhibitor for the treatment of hematological malignancies[J]. Anticancer Drugs，2018，29（10）：995-1003.

INFANTE P，ALFONSI R，INGALLINA C，et al. Inhibition of hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype[J]. Cell Death Dis，2016，7（9）：e2376.

ALFONSI R，BOTTA B，CACCHI S，et al. Design，palladium-catalyzed synthesis，and biological investigation of 2-substituted 3-aroylquinolin-4（1H）-ones as inhibitors of the hedgehog signaling pathway[J]. J Med Chem，2017，60（4）：1469-1477.

SCHAEFER G I，PEREZ J R，DUVALL J R，et al. Disco-very of small-molecule modulators of the Sonic hedgehog pathway[J]. J Am Chem Soc，2013，135（26）：9675-9680.

SOLINAS A，FAURE H，ROUDAUT H，et al. Acyl-thiourea，acylurea，and acylguanidine derivatives with potent hedgehog inhibiting activity[J]. J Med Chem，2012，55（4）：1559-1571.

AGYEMAN A，JHA B K，MAZUMDAR T，et al. Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding[J]. Oncotarget，2014，5（12）：4492-4503.

GOLDMAN J，ECKHARDT S G，BORAD M J，et al. Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors[J]. Clin Cancer Res，2015，21（5）：1002-1009.

BOSCO-CLÉMENT G，ZHANG F，CHEN Z，et al. Targeting Gli transcription activation by small molecule suppresses tumor growth[J]. Oncogene，2014，33（16）：2087-2097.

BEAUCHAMP E M，RINGER L，BULUT G，et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/Gli pathway[J]. J Clin Invest，2011，121（1）：148-160.

LI B，FEI D L，FLAVENY C A，et al. Pyrvinium atte-nuates hedgehog signaling downstream of smoothened[J]. Cancer Res，2014，74（17）：4811-4821.

DIDIASOVA M，SINGH R，WILHELM J，et al. Pirfenidone exerts antifibrotic effects through inhibition of Gli transcription factors[J]. FASEB J，2017，31（5）：1916-1928.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

液相微萃取技术的研究进展及其在中药分析中的应用

米非司酮在妇产科的应用研究进展

他汀类药物的临床多效性研究进展

降低非甾体抗炎药致胃肠道不良反应的方法研究进展

金匮肾气丸（片、煎剂）的临床应用进展

Related Author

程艳芹李明春纪松岗

彭茸赵纯全

杨冬梅袁白杨

甄细娥王宽宗鸣蒋蕾高赛男陈淑欣李森

吴春芝岳文谷福根

谭谡

张培?单葵?

司继刚曹原赵群

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰